VolitionRx Limited (NYSE American: VNRX) announced clinical study results showing its Nu.Q Vet Feline assay achieved high accuracy in detecting lymphoma, the most common cancer in cats. The blood-based test detected more than 80% of feline lymphomas with 100% specificity, meaning no false positives occurred in the study.
The company stated that feline cancer has historically been difficult to diagnose early, often requiring invasive biopsies or costly imaging after symptoms have progressed. Veterinarians have sought a feline screening solution for years, and this test could address that need. Following the international rollout of its canine cancer test, VolitionRx has now demonstrated the technology's effectiveness in cats.
VolitionRx plans to complete product development and make the Nu.Q Vet Feline Test available through existing distribution networks, including reference laboratories and point-of-care platforms. The company expects this to become the world's first simple and affordable liquid biopsy test for feline cancer.
Volition is a multinational company focused on advancing the science of epigenetics and is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. For further information, visit the company's website at https://volition.com/.
The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology and life sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers various communication solutions. For more information about BioMedWire, visit https://www.BioMedWire.com.
This development represents a significant advancement in veterinary diagnostics, potentially enabling earlier detection of feline lymphoma when treatment options are more effective. The availability of a simple blood test could transform how veterinarians screen for and monitor cancer in cats, reducing the need for invasive procedures and potentially improving survival rates. For pet owners, this technology could mean earlier intervention and better outcomes for their feline companions.
The implications extend beyond veterinary medicine, as successful implementation in animal health could validate the technology for broader applications. VolitionRx's work in epigenetics and liquid biopsy technology demonstrates how medical innovations can cross species boundaries, potentially informing human cancer detection methods. The company's progress in both canine and feline cancer detection suggests a scalable approach to disease screening that could impact multiple areas of healthcare.
